Strategies to AchieVe Viral Suppression for Youth With HIV

Launched by JOHNS HOPKINS UNIVERSITY · Mar 14, 2025

Keywords

ClinConnect Summary

The SAVVY Study is looking to improve the health of young people living with HIV by exploring better ways to help them manage their treatment. Even though there are effective treatments available, many adolescents and young adults struggle to keep their HIV under control, which can lead to serious health risks. This trial aims to give participants more choices for their HIV medications, including options for long-acting injections that don't require daily pills. The study will also help participants overcome any obstacles they face in accessing these treatments and will gather important information to improve care for young people with HIV.

To be eligible for the study, participants need to be between 12 and 24 years old, currently taking HIV medication, and willing to communicate with their healthcare provider about their treatment. However, individuals with certain health issues, specific medication interactions, or severe mental health challenges may not qualify. Those who join can expect support in finding the best treatment option for them and guidance throughout the process. This study is an important step in helping young people achieve better health outcomes and ultimately reducing the impact of HIV in their lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • prescribed ART,
• • willing to sign informed consent (including communication with one's primary HIV provider)
• Exclusion Criteria:
• • Relevant drug resistance mutations (per medical record) that compromises activity of Cabotegravir (CBG) + rilpivirine (RPV)
• • disallowed medications,
• • pregnancy.
• • Mental health, cognitive, or behavioral dysfunction that in the opinion of the site PI would impair participation;
• • severe illness/hospitalization at the time of enrollment,
• • plan to move away in the next 12 months.